Liu J, Li X, Fan L, Yang J, Wang J, Sun J, Wang Z. Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci. 2019;218:213–23.
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–15.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.
Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112:95–101.
Haschka J, Kraus DA, Behanova M, Huber S, Bartko J, Schanda JE et al. Fractal-based analysis of bone microstructure in Crohn’s disease: a pilot study. J Clin Med. 2020;9(12):4116
Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437–42.
Taguchi A, Suei Y, Ohtsuka M, Otani K, Tanimoto K, Ohtaki M. Usefulness of panoramic radiography in the diagnosis of postmenopausal osteoporosis in women. Width and morphology of inferior cortex of the mandible. Dentomaxillofac Radiol. 1996;25:263–7
Klemetti E, Kolmakov S, Kröger H. Pantomography in assessment of the osteoporosis risk group. Scand J Dent Res. 1994;102(1):68–72.
Demiralp KÖ, Kurşun-Çakmak EŞ, Bayrak S, Akbulut N, Atakan C, Orhan K. Trabecular structure designation using fractal analysis technique on panoramic radiographs of patients with bisphosphonate intake: a preliminary study. Oral Radiol. 2019;35(1):23–8.
Amer ME, Heo MS, Brooks SL, Benavides E. Anatomical variations of trabecular bone structure in intraoral radiographs using fractal and particles count analyses. Imaging Sci Dent. 2012;42(1):5–12.
Kato CN, Barra SG, Pereira MJ, Gomes LT, Amaral TM, Abreu LG, et al. Mandibular radiomorphometric parameters of women with cemento-osseous dysplasia. Dentomaxillofac Radiol. 2020;49(4):20190359.
White SC, Rudolph DJ. Alterations of the trabecular pattern of the jaws in patients with osteoporosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:628–35.
Coşgunarslan A, Canger EM, Soydan Çabuk D. Proton pump inhibitors and mandibular bone quality: a preliminary study. Dentomaxillofac Radiol. 5:20200505. doi: https://doi.org/10.1259/dmfr.20200505. [Online ahead of print]
Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. Am J Ment Defic. 1981;86(2):127–37.
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82.
Buckland-Wright JC, Lynch JA, Rymer J, Fogelman I. Fractal signature analysis of macroradiographs measures trabecular organization in lumbar of postmenopausal women. Calcif Tissue Int. 1994;54:106–12.
Aktuna Belgin C, Serindere G. Fractal and radiomorphometric analysis of mandibular bone changes in patients undergoing intravenous corticosteroid therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(1):110–5.
Kavitha MS, Park SY, Heo MS, Chien SI. Distributional variations in the quantitative cortical and trabecular bone radiographic measurements of mandible, between male and female populations of Korea, and its utilization. PLoS One. 2016;11: e0167992
Apolinario AC, Sindeaux R, de Souza Figueiredo PT, Guimaraes AT, Acevedo AC, Castro LC, et al. Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment. Dentomaxillofac Radiol. 2016;45:20150400.
Jacobs CR. The mechanobiology of cancellous bone structural adaptation. J Rehabil Res Dev. 2000;37(2):209–16.
Russo CR, Lauretani F, Bandinelli S, et al. Aging bone in men and women: beyond changes in bone mineral density. Osteoporos Int. 2003;14(7):531–8.
O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.
Freedberg D, Haynes K, Denburg M, Zemel B, Leonard M, Abrams J, Yang YX. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26:2501–7.
Lewis JR, Barre D, Zhu K, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Minerl Res. 2014;29:2489–97.
Gagnemo-Persson R, Samuelsson A, Hakanson R, Persson P. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997;61:210–5.
Park JH, Song YM, Jung JH, Han K. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study. Bone. 2020;135:115306
Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, et al. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab. 2016;34(5):571–9.
Stathopoulos KD, Zoubos AB, Papaioannou NA, Mastrokalos D, Galanos A, Papagelopoulos PJ, et al. Differences of bone mineral mass, volumetric bone mineral density, geometrical and structural parameters and derived strength of the tibia between premenopausal and postmenopausal women of different age groups: a peripheral Quantitative Computed Tomography (pQCT) study. J Musculoskelet Neuronal Interact. 2016;16(2):113–21.
Lauretani F, Bandinelli S, Russo CR, Maggio M, Di Iorio A, Cherubini A, et al. Correlates of bone quality in older persons. Bone. 2006;39(4):915–21.
van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters GMEEG. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone. 2015;81:675–682
Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903–10.
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.
Fattahi MR, Niknam R, Shams M, Anushiravani A, Taghavi SA, Omrani GR, et al. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density. Risk Manag Healthc Policy. 2019;12:349–55.
